which glp 1 is best for inflammation

Which GLP-1 Is Best for Inflammation? UK Evidence Review

12
 min read by:
Fella Health

Glucagon-like peptide-1 (GLP-1) receptor agonists are medications licensed in the UK for managing type 2 diabetes and, in some cases, obesity. Emerging research suggests these drugs may possess anti-inflammatory properties beyond their established metabolic effects. However, no GLP-1 receptor agonist is currently licensed specifically for treating inflammatory conditions, and there is no definitive evidence establishing superiority of one agent over another for anti-inflammatory purposes. This article examines the potential anti-inflammatory mechanisms of GLP-1 medications, compares available agents, and discusses what patients should consider when speaking with their GP about these treatments.

Quick Answer: No single GLP-1 receptor agonist has been proven superior for anti-inflammatory effects, as these medications are not licensed for treating inflammation in the UK.

  • GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) are licensed for type 2 diabetes and weight management, not inflammatory conditions.
  • These medications may reduce inflammatory markers like C-reactive protein through direct immune modulation and indirect metabolic improvements.
  • Clinical evidence suggests potential benefits in cardiovascular disease and non-alcoholic fatty liver disease, though anti-inflammatory effects remain investigational.
  • Prescribing decisions should follow NICE guidance based on diabetes control or weight management criteria, with regular monitoring for side effects including pancreatitis and gallbladder disease.

Understanding GLP-1 Receptor Agonists and Inflammation

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily licensed in the UK for managing type 2 diabetes mellitus and, in some cases, obesity or weight management. These drugs work by mimicking the action of naturally occurring GLP-1, an incretin hormone that stimulates insulin secretion in response to food intake, suppresses glucagon release, and slows gastric emptying. GLP-1 receptor agonists available in the UK include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and lixisenatide (Lyxumia). Exenatide products have limited availability in the UK. This list is not exhaustive; other agents may hold UK authorisation and a prescriber or pharmacist can advise on current availability.

Beyond their established metabolic effects, emerging research suggests that GLP-1 receptor agonists may possess anti-inflammatory properties. Chronic low-grade inflammation is increasingly recognised as a key contributor to numerous conditions, including cardiovascular disease, metabolic syndrome, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease or NAFLD), and certain autoimmune disorders. The potential anti-inflammatory effects of GLP-1 medications have generated considerable interest among researchers and clinicians.

It is important to note that GLP-1 receptor agonists are not licensed as primary anti-inflammatory agents in the UK. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved these medications for glycaemic control and weight management. One exception is Wegovy (semaglutide injection 2.4 mg), which holds a UK licence for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and F2 to F3 liver fibrosis (per the Wegovy UK SmPC). Current NICE guidance (NG28 for type 2 diabetes, TA875 for semaglutide 2.4 mg, and TA664 for liraglutide 3.0 mg) does not include inflammatory conditions as commissioning indications.

The relationship between GLP-1 receptor agonists and inflammation remains an active area of clinical investigation, with ongoing studies exploring mechanisms and clinical applications beyond traditional metabolic indications.

How GLP-1 Medications May Affect Inflammatory Markers

The mechanisms through which GLP-1 receptor agonists may reduce inflammation are multifaceted and not yet fully understood. Research suggests these medications may influence inflammatory pathways both directly and indirectly. GLP-1 receptors are expressed not only in pancreatic beta cells but also in various tissues including the cardiovascular system, kidneys, and immune cells such as macrophages and lymphocytes.

Potential direct anti-inflammatory mechanisms from preclinical and early clinical studies include:

  • Modulation of immune cell function: GLP-1 receptor activation may reduce pro-inflammatory cytokine production from macrophages and other immune cells

  • Reduction of oxidative stress: These medications may decrease reactive oxygen species production, which contributes to inflammatory processes

  • Endothelial protection: GLP-1 receptor agonists may improve endothelial function and reduce vascular inflammation

  • Inhibition of inflammatory signalling pathways: Including suppression of nuclear factor-kappa B (NF-kB), a key regulator of inflammatory gene expression

Many of these mechanisms have been primarily demonstrated in laboratory or animal studies, with more limited evidence in humans.

Indirect anti-inflammatory effects likely result from the metabolic improvements these medications produce. Weight loss, improved glycaemic control, and reduced insulin resistance all contribute to decreased systemic inflammation. Adipose tissue, particularly visceral fat, is metabolically active and produces pro-inflammatory cytokines; reduction in adiposity therefore naturally lowers inflammatory burden.

Clinical studies have demonstrated that GLP-1 receptor agonists can reduce various inflammatory biomarkers, including:

  • C-reactive protein (CRP): A general marker of systemic inflammation

  • Interleukin-6 (IL-6): A pro-inflammatory cytokine

  • Tumour necrosis factor-alpha (TNF-alpha): Another key inflammatory mediator

  • Plasminogen activator inhibitor-1 (PAI-1): Associated with cardiovascular inflammation

The magnitude of these effects varies between studies and may depend on baseline inflammatory status, degree of weight loss achieved, and individual patient characteristics. Changes in these biomarkers are surrogate endpoints and have not been validated as a basis for selecting one specific GLP-1 receptor agonist over another for anti-inflammatory purposes.

Semaglutide

UK Brand Names: Ozempic, Wegovy, Rybelsus

Administration: Once-weekly injection or daily oral tablet

Key Cardiovascular Trial: SUSTAIN-6; STEP programme

Evidence for Inflammatory Marker Reduction: Reduces CRP, IL-6; NASH trial showed hepatic inflammation improvement (NEJM 2021)

Weight Loss Efficacy: Highest among available agents; up to ~15% body weight

NICE Guidance: NG28 (T2DM); TA875 (2.4 mg for obesity)

Liraglutide

UK Brand Names: Victoza, Saxenda

Administration: Once-daily subcutaneous injection

Key Cardiovascular Trial: LEADER trial; cardiovascular benefit demonstrated

Evidence for Inflammatory Marker Reduction: Reductions in CRP, TNF-α; some evidence of immune cell modulation

Weight Loss Efficacy: Moderate; up to ~8% body weight

NICE Guidance: NG28 (T2DM); TA664 (3.0 mg for obesity)

Dulaglutide

UK Brand Names: Trulicity

Administration: Once-weekly subcutaneous injection

Key Cardiovascular Trial: REWIND trial; cardiovascular benefit demonstrated

Evidence for Inflammatory Marker Reduction: Improvements in inflammatory markers; effects likely secondary to metabolic improvement

Weight Loss Efficacy: Moderate; up to ~3–5% body weight

NICE Guidance: NG28 (T2DM); not licensed for obesity

Lixisenatide

UK Brand Names: Lyxumia

Administration: Once-daily subcutaneous injection

Key Cardiovascular Trial: ELIXA trial; neutral cardiovascular outcome

Evidence for Inflammatory Marker Reduction: Similar class effects on inflammatory markers; less data than newer agents

Weight Loss Efficacy: Lower than semaglutide or liraglutide

NICE Guidance: NG28 (T2DM); not licensed for obesity

Exenatide

UK Brand Names: Limited UK availability

Administration: Twice-daily or once-weekly injection

Key Cardiovascular Trial: EXSCEL trial; neutral cardiovascular outcome

Evidence for Inflammatory Marker Reduction: Some anti-inflammatory effects in research settings; less robust than semaglutide data

Weight Loss Efficacy: Lower than semaglutide; limited UK use

NICE Guidance: NG28 (T2DM); limited NICE guidance

Comparing Anti-Inflammatory Effects Across GLP-1 Drugs

When considering which GLP-1 receptor agonist might offer the greatest anti-inflammatory benefit, it is crucial to recognise that there is currently no definitive evidence establishing superiority of one agent over another specifically for anti-inflammatory effects. Head-to-head comparative trials examining inflammatory outcomes as primary endpoints are limited, and most evidence comes from individual studies or post-hoc analyses of cardiovascular outcome trials.

Semaglutide, available as once-weekly injection (Ozempic, Wegovy) or daily oral tablet (Rybelsus), has demonstrated robust effects on weight loss and cardiovascular outcomes in the SUSTAIN and STEP trial programmes. Studies suggest semaglutide may reduce CRP and other inflammatory markers, though these effects may be largely attributable to significant weight reduction rather than direct anti-inflammatory action.

Liraglutide (Victoza for diabetes, Saxenda for weight management) is administered as a daily subcutaneous injection. The LEADER cardiovascular outcomes trial demonstrated cardiovascular benefits, and subsequent analyses have shown reductions in inflammatory biomarkers.[1][10] Distinguishing these effects from those secondary to weight loss and metabolic improvement remains challenging.

Dulaglutide (Trulicity), a once-weekly injection, has also shown cardiovascular benefits in the REWIND trial. Studies indicate improvements in inflammatory markers, though again, separating direct anti-inflammatory effects from those secondary to metabolic improvement is difficult.

Lixisenatide (Lyxumia) is a daily GLP-1 receptor agonist available in the UK. Its effects on inflammatory markers appear broadly similar to other agents in the class, though it may produce less weight loss than newer agents such as semaglutide.

Exenatide products have had limited availability in the UK; prescribers should verify current availability. While exenatide has demonstrated some anti-inflammatory effects in research settings, newer agents generally produce greater weight loss and may therefore have more pronounced effects on inflammation-related markers.

The practical reality is that differences in anti-inflammatory effects between GLP-1 receptor agonists are likely modest and may be overshadowed by individual patient response, tolerability, and the degree of metabolic improvement achieved. NICE guidance (NG28) does not differentiate between agents based on anti-inflammatory properties, and no agent should be selected primarily on this basis.

Clinical Evidence for GLP-1s in Inflammatory Conditions

Whilst GLP-1 receptor agonists are not licensed as primary treatments for inflammatory diseases (with the exception noted below), emerging clinical evidence suggests potential benefits in several conditions characterised by chronic inflammation. These remain largely investigational applications, and patients should not alter prescribed treatments without medical supervision.

Cardiovascular disease: The most robust evidence for anti-inflammatory benefits comes from cardiovascular outcomes trials. Studies including LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) have demonstrated reduced cardiovascular events in patients with type 2 diabetes.[2] Whilst multiple mechanisms likely contribute, including improved glycaemic control, weight loss, and blood pressure reduction, changes in vascular inflammation may play a role. Improvements in endothelial function and decreased arterial stiffness have been documented.

Liver disease (MASH/MASLD): Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and the broader spectrum of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) involve hepatic inflammation and are closely linked to metabolic syndrome. Wegovy (semaglutide 2.4 mg injection) is UK-licensed for adults with non-cirrhotic MASH and F2 to F3 liver fibrosis (Wegovy UK SmPC, section 4.1). A phase 2 trial published in the New England Journal of Medicine (2021) showed NASH resolution in a significantly greater proportion of participants receiving semaglutide compared with placebo, though effects on fibrosis were uncertain. NHS access to Wegovy for the MASH indication depends on NICE guidance and local ICB commissioning decisions, so patients should discuss this with their specialist.

Chronic kidney disease: Inflammation contributes to progressive kidney damage in diabetic nephropathy. The FLOW trial (semaglutide, published 2024) demonstrated a significant reduction in the risk of major kidney disease events in people with type 2 diabetes and chronic kidney disease. GLP-1 receptor agonists may slow kidney function decline through anti-inflammatory mechanisms alongside improved glycaemic control and blood pressure reduction. Prescribing should follow current NICE guidance and licensing indications.

Psoriasis and inflammatory skin conditions: Small studies have explored GLP-1 receptor agonists in psoriasis, an inflammatory skin condition often associated with metabolic syndrome. Preliminary evidence suggests potential benefits, though larger trials are needed before any clinical recommendations can be made.

Inflammatory bowel disease and rheumatological conditions: Research in these areas remains very limited, with mostly preclinical or small observational studies. There is currently no official recommendation for using GLP-1 receptor agonists as primary treatment for these conditions.

Patients interested in potential anti-inflammatory benefits should discuss the evidence and its limitations with their GP or specialist, recognising that these medications are prescribed primarily for metabolic indications according to NICE guidance.

Choosing a GLP-1: What to Discuss with Your GP

If you are considering a GLP-1 receptor agonist and are interested in potential anti-inflammatory benefits, several important factors should guide the conversation with your GP or diabetes specialist. The choice of medication should be individualised based on your specific medical needs, comorbidities, and treatment goals.

Key discussion points include:

  • Primary indication: GLP-1 receptor agonists are prescribed for type 2 diabetes management (NICE NG28) or, in specific circumstances, weight management (NICE TA875 for semaglutide 2.4 mg; TA664 for liraglutide 3.0 mg). Your eligibility depends on meeting NICE criteria, which typically include inadequate glycaemic control despite other medications or specific BMI thresholds for weight management indications. NHS access to weight-management GLP-1 receptor agonists also depends on local Integrated Care Board (ICB) commissioning decisions and specialist weight-management pathways, which vary by area.

  • Cardiovascular risk: If you have established cardiovascular disease or high cardiovascular risk, your clinician may favour agents with proven cardiovascular benefits in outcome trials, such as semaglutide, liraglutide, or dulaglutide.

  • Weight management goals: If significant weight loss is a priority (which itself reduces inflammation), higher-efficacy agents like semaglutide may be preferred, though individual response varies.

  • Administration preferences: Consider whether you prefer once-weekly injections (semaglutide, dulaglutide), daily injections (liraglutide, lixisenatide), or oral medication (oral semaglutide), as adherence is crucial for achieving benefits.

  • Tolerability and side effects: Common adverse effects include nausea, vomiting, diarrhoea, and constipation, which typically improve over time. Other important side effects include gallbladder disease (cholelithiasis, cholecystitis), and potential worsening of diabetic retinopathy complications, particularly in people with pre-existing pre-proliferative or proliferative diabetic retinopathy and in those who experience rapid HbA1c reduction. Rare but serious risks include pancreatitis. Animal studies have raised a theoretical concern regarding thyroid C-cell tumours, though this has not been established in humans. Your GP will assess your individual risk factors.

Important safety considerations:

  • Seek urgent same-day medical assessment via NHS 111 or A&E for severe abdominal pain (potential pancreatitis) and stop taking the medication pending review

  • Report persistent nausea, vomiting, or signs of dehydration

  • Be aware of increased hypoglycaemia risk if taking insulin or sulfonylureas (dose adjustments may be needed)

  • Attend regular monitoring appointments for kidney function, diabetic retinopathy, and other parameters; those with pre-existing retinopathy should ensure appropriate ophthalmic follow-up

  • Discuss contraception if you are of childbearing potential, as GLP-1 receptor agonists are generally not recommended during pregnancy or breastfeeding[11]

  • Report any suspected side effects via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk

Specific administration requirements vary by product. For example, oral semaglutide (Rybelsus) must be taken on an empty stomach with a small amount of water, waiting 30 minutes before eating, drinking, or taking other medications.

Remember that anti-inflammatory effects, whilst potentially beneficial, are not the primary reason for prescribing these medications. The decision should be based on established indications, with any anti-inflammatory benefits considered as potential additional advantages rather than the main treatment goal.

Scientific References

  1. .
  2. .
  3. .
  4. .
  5. .
  6. .
  7. .
  8. .
  9. .
  10. .
  11. .
  12. .
  13. .
  14. .
  15. .
  16. .

Frequently Asked Questions

Are GLP-1 receptor agonists approved for treating inflammation in the UK?

No, GLP-1 receptor agonists are not licensed by the MHRA specifically for treating inflammatory conditions. They are approved for managing type 2 diabetes mellitus and, in certain cases, obesity according to NICE guidance.

How do GLP-1 medications reduce inflammatory markers?

GLP-1 receptor agonists may reduce inflammation through direct mechanisms (modulating immune cell function, reducing oxidative stress) and indirect effects from weight loss and improved metabolic control. Clinical studies show reductions in C-reactive protein, interleukin-6, and other inflammatory biomarkers.

Which GLP-1 medication has the strongest anti-inflammatory effects?

There is currently no definitive evidence establishing that one GLP-1 receptor agonist is superior to another specifically for anti-inflammatory effects. Differences between agents like semaglutide, liraglutide, and dulaglutide are likely modest and may be overshadowed by individual patient response and degree of metabolic improvement achieved.


Editorial Policy

All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.

Disclaimer

This content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.

Book a discovery call

and discuss your eligibility for the Fella Program

Book your free call